The p53 tumor suppressor is regulated by the MDM2 oncoprotein. Overexpression of MDM2 maintains p53 at low levels and contributes to the functional inactivation of p53 in a subset of tumors. We found that treatment with roscovitine and olomoucin, which were originally developed as cyclin-dependent kinase (CDK) inhibitors, can eciently stabilize and activate nuclear p53 in tumor cells with MDM2 ampli®cation or cytoplasmic p53. These inhibitors block the degradation of p53 without aecting p53-MDM2 binding and the nuclear shuttling function of p53 and MDM2. Roscovitine also induces stabilization of the p53 Ala-315 mutant, indicating that it does not act by regulating the CDK phosphorylation of serine 315. Roscovitine induces down-regulation of MDM2 expression at both protein and mRNA levels. Ectopic expression of MDM2 can abrogate the ability of roscovitine to induce p53 stabilization. Low concentrations of roscovitine cooperate with the DNA-damaging agent camptothecin to activate p53 in a synergistic fashion. These results show that the small molecule CDK inhibitors can be used to activate p53 through their potent inhibitory eect on MDM2 expression and may be useful as sensitizing agents for other DNA-damaging drugs. Oncogene (2001) 20, 3206 ± 3216.
Introduction
The p53 tumor suppressor is an ecient inducer of growth arrest and apoptosis in response to a variety of stress signals associated with malignant cell proliferation or DNA damage. In the absence of stress, p53 is maintained at a low level to prevent interference with normal cell proliferation. This is achieved by expression of the MDM2 oncoprotein, which binds to p53 and promotes p53 degradation by the ubiquitindependent proteasomes (Juven-Gershon and Oren, 1999) . Both MDM2 and p53 have nuclear localization and nuclear export signals and can shuttle between the nucleus and the cytoplasm (Roth et al., 1998; Stommel et al., 1999) . Ecient degradation of p53 requires nuclear export of MDM2 (Tao and Levine, 1999) . Wild type p53 accumulates in the cytoplasm in certain types of tumors through a dynamic process involving active nuclear import and export of p53 (Moll et al., 1992 (Moll et al., , 1995 Stommel et al., 1999; Lu et al., 2000) . Expression of MDM2 is important for the maintenance of p53 nuclear exclusion and rapid degradation in tumor cells (Lu et al., 2000) . MDM2 overexpression due to gene ampli®cation occurs in *30% of sarcomas (Oliner et al., 1992; Cordon Cardo et al., 1994) , which may contribute to functional inactivation of p53.
Activation of p53 leads to growth arrest or apoptosis, which may be bene®cial for cancer treatment. At present, several mechanisms are known to activate p53. DNA-damaging agents can cause accumulation of p53 in the nucleus by inducing phosphorylation of p53 and inhibition of MDM2 binding (Shieh et al., 2000; Chehab et al., 2000; Hirao et al., 2000) . UV irradiation induces phosphorylation of p53 and rapid down-regulation of MDM2 expression at the transcription level (Lu et al., 1998; Kapoor et al., 2000; Wu and Levine, 1997) . Activation of oncogenes can induce expression of the tumor suppressor ARF, which induces nuclear p53 accumulation by binding to and inactivating MDM2 (Sherr, 1998) . Arti®cial fusion proteins that compete with p53 for MDM2 binding can activate p53 in the absence of DNA damage (Bottger et al., 1997) . Antisense inhibition of MDM2 also eciently activates p53 in cell culture (Chen et al., 1998) . However, the later approaches require delivery of large molecules, which may be a limiting factor for practical use. Therefore, identi®cation of cell-permeable small molecules that can activate p53 by mechanisms distinct from induction of DNA damage may be useful for complementing or enhancing the eects of conventional chemotherapy drugs.
It has been shown that p53 has a phosphorylation site for the CDC2 cyclin-dependent kinase (Bischo et al., 1990; Addison et al., 1990) . The serine residue of this CDK site (Ser-312 in mouse p53 and Ser-315 in human p53) is localized adjacent to the major nuclear localization signal of p53 (residue 316 ± 322 in human p53) (Shaulsky et al., 1990) . This serine residue is a substrate for puri®ed CDC2 in vitro and is phosphorylated in vivo (Bischo et al., 1990; Addison et al., 1990) . p53 is also phosphorylated by CDK2 in vitro (Wang and Prives, 1995) , which results in enhanced DNA binding. Furthermore, phosphorylated Ser-315 has recently been shown to be the substrate of the cell cycle-related CDC14 phosphatase in vitro (Li et al., 2000) . However, in vivo analyses found that mutation of Ser-315 does not aect the ability of p53 to induce growth suppression and transcription activation, and to respond to DNA damage (Blattner et al., 1999; Slingerland et al., 1993; Hao et al., 1996) . Therefore, whether p53 is regulated by the cell cycle and the role of the CDK site in this process is still unclear.
Previous studies showed that nuclear exclusion of p53 in the breast tumor cell line MCF-7 is associated with G1 phase of the cell cycle (David-Pfeuty et al., 1996) . Our experiments revealed that the expression and function of MDM2 is also essential for the nuclear exclusion of p53 in this cell line (Lu et al., 2000) . In this study, we investigated the eects of CDK inhibitor roscovitine and olomoucin in order to determine whether CDK or cell cycle status aects p53 stability and localization by modulating its sensitivity to MDM2. The results show that these inhibitors eciently induce stabilization and activation of p53 even in cell lines with MDM2 gene ampli®cation. However, the mechanism of p53 stabilization by the CDK inhibitors appears to mainly involve downregulation of MDM2 and does not require modulation of p53 serine 315 phosphorylation. Consistent with its mechanism of p53 stabilization, roscovitine synergistically enhanced the ability of the DNA-damaging drug camptothecin in the activation of p53.
Results

Cdk inhibitors induce nuclear accumulation and activation of p53
Previous studies showed that wild type p53 can be inactivated by nuclear exclusion or MDM2 ampli®ca-tion. The breast tumor cell line MCF-7 shows distinct cytoplasmic accumulation of p53, which is due to active nuclear export mediated by MDM2 (Lu et al., 2000) . The SJSA cells contain MDM2 gene ampli®ca-tion and also express very low levels of wild type p53 (Leach et al., 1993; Chen et al., 1999) . We found that several compounds originally developed as CDK inhibitors (Vesely et al., 1994; Meijer et al., 1997) , including roscovitine, olomoucin, and¯avopiridol were able to induce strong nuclear p53 accumulation in MCF-7 and SJSA cells ( Figure 1a , and data not shown). Roscovitine induced strong nuclear accumulation of p53 when used at concentrations above 10 mM (Figure 1a) . A similar eect was also obtained using 100 mM of the less potent inhibitor olomoucine (data not shown).
The eects of the drugs were then tested in a panel of tumor cells with wild type p53, including U2OS, JAR, PA-1, WI38, and SK-N-SH. All of the cell lines accumulated nuclear p53 after treatment with roscovitine at concentrations that are relatively selective for CDK (10 ± 20 mM) (Meijer et al., 1997) . Of particular interest, the inhibitors were eective in inducing nuclear p53 accumulation in the SJSA and JAR cells (containing MDM2 gene ampli®cation) and the SK-N-SH and MCF-7 cells (containing cytoplasmic p53). These results suggest that the CDK inhibitors are highly ecient in overcoming the eect of MDM2.
To determine whether the nuclear p53 induced by roscovitine treatment is functionally active, MCF-7 and U2OS cells stably transfected with the p53-responsive BP100-luciferase reporter were tested. BP100-luciferase contains the p53-responsive element from the MDM2 gene (Wu et al., 1993) . Treatment with roscovitine led to a 4 ± 8-fold increase of luciferase activity at a dose dependent fashion (Figure 1b) , indicating that p53 induced by the drug was functionally active. However, p53 transcription activity readout diminished at high concentrations of roscovitine (40 mM). The eect of roscovitine on the p53-responsive reporter was dependent on the expression of p53. The p53-null H1299 cells stably transfected with the BP100-luciferase plasmid showed a less than twofold induction by roscovitine (data not shown).
Because the CDK inhibitors also induced moderate levels of cell death in these experiments, it is possible that the cytotoxic eects of these compounds interfere with the functional readout of p53 activity. Therefore, cells were treated with roscovitine for 14 h and then cultured in drug-free medium. The results showed a dramatic increase of p53 transcription activity after removing roscovitine (4700-fold compared to untreated cells), which peaked at 8 ± 14 h after drug removal in the MCF-7 cells (Figure 1c ). Therefore, treatment and then removal of the drug can lead to strong activation of p53. This result suggests that the p53 induced by roscovitine was functional but its true activity was partially obscured by other activities of the drug.
The fact that roscovitine and olomoucin are relatively speci®c inhibitors of CDK led us to investigate whether inhibition of CDK is involved in the activation of p53. CDK dominant-negative mutants (cdc2DN, cdk2DN, cdk3DN, cdk4DN , and cdk6DN (Heuvel and Harlow, 1993) ) and CDK inhibitors (p16, p21, p27, and p57) were transiently transfected into MCF-7 cells individually or in combination. These experiments did not result in signi®cant induction of nuclear p53 accumulation or reproducible increase in p53 transcription function (data not shown). Infection with a p16 adenovirus, which induced G1 arrest and apoptosis in MCF-7 cells, also did not induce nuclear p53 accumulation (data not shown). A previous study using p21 adenovirus also did not induce accumulation of p53 (Meng et al., 1998) . These results, as well as the data described below suggest that inhibition of CDK is not responsible for the activation of p53 by roscovitine.
Regulation of p53, MDM2 and p21 expression by CDK inhibitors
To determine whether treatment with CDK inhibitors induces endogenous p53-responsive gene expression,
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The cdk inhibitor roscovitine activates p53 by inhibiting MDM2 expression W Lu et al the levels of p53, p21 (WAF1) and MDM2 were determined by Western blot. The inhibitors induced signi®cant increase in p53 level in MCF-7, SJSA and JAR cells. The level of p21 expression was also induced with delayed timing compared to the rise of p53 level (Figure 2a) . Unexpectedly, the level of MDM2 decreased rapidly after treatment. This pattern of response was observed in six cell lines (SJSA, JAR, MCF7, HCT116, WI38 and U2OS), two of which contain MDM2 ampli®cation. The decrease in MDM2 expression appeared to be relatively speci®c after treatment with 20 mM of roscovitine, since p21 level ( Figure 2a ) and BP100-luciferase expression ( Figure  1b ) did not decrease after treatment. Removal of the drug after a 14-h treatment rapidly restored MDM2 expression to levels higher than untreated cells, which was associated with a decrease of p53 level ( Figure 2b ). These results show that roscovitine selectively inhibits the expression of MDM2, which may be responsible for the stabilization and accumulation of p53.
Next, the mechanism of MDM2 inhibition by CDK inhibitors was investigated. The rate of MDM2 degradation was determined by treatment with the protein synthesis inhibitor cyclohexamide followed by Western blot analysis of MDM2. Roscovitine did not enhance the rate of MDM2 degradation (data not shown). Northern blot analysis revealed that roscovitine induced rapid decrease in MDM2 mRNA level in several cell lines examined, including MCF7, HCT116 and JAR ( Figure 3a , and data not shown), suggesting that inhibition of MDM2 transcription or promotion of mRNA degradation may be responsible for down- 
Effects of CDK inhibitors on p53 stability
The down-regulation of MDM2 by roscovitine suggested that induction of p53 was due to stabilization. Therefore, the stability of p53 in roscovitine-treated cells was determined by 35 S-methionine metabolic labeling and pulse-chase analysis. In SJSA cells, p53 had a half-life of approximately 30 min, which was extended to about 4 h after roscovitine treatment ( Figure 4a ). Western blot of SJSA cells lysed in a hypotonic buer (see Materials and methods) showed a series of high molecular weight p53 bands. After incubating the extract at 308C for 2 h, the high molecular weight p53 bands collapsed into the 53 kd form, suggesting that these bands were polyubiquitinated p53 that were deubiquitinated by the in vitro incubation. Treatment with roscovitine for 8 h signi®cantly reduced the amount of high molecular weight forms of p53 (Figure 4b ), suggesting that the drug inhibited p53 ubiquitination, possibly by down-regulation of MDM2.
In order to test whether roscovitine also blocked the formation of p53-MDM2 complex, the ability of MDM2 to coprecipitate with p53 was determined. The result suggested that roscovitine did not abrogate complex formation in cells (data not shown). However, the change of MDM2-p53 ratio after roscovitine treatment also made it dicult to determine whether there was change in the eciency of binding. Therefore, the ability of MDM2 and p53 from roscovitinetreated cells to interact with GST-p53 or GST-MDM2 MCF-7 cells were pre-treated with 20 mM roscovitine for 14 h and then refed with drug-free medium for the indicated times. MDM2, p21 and p53 levels were detected by Western blot Oncogene The cdk inhibitor roscovitine activates p53 by inhibiting MDM2 expression W Lu et al in vitro was tested. Incubation of cell lysate with glutathione agarose beads loaded with identical amounts of GST-MDM2 recovered a signi®cant amount of p53. A deletion protein GST-MDM384-491 without the p53-binding domain did not capture p53 from the lysate, indicating that the assay was highly speci®c. p53 from roscovitine-treated cells also bound to GST-MDM2 with similar eciency (Figure  4c ), con®rming that treatment with roscovitine does not result in modi®cation of p53 and reduction in its MDM2-binding anity. In a reciprocal assay, GSTp53 also captured MDM2 from roscovitine-treated or control cell lysate with similar eciency (data not shown).
Stabilization of p53 by roscovitine requires inhibition of MDM2 expression
Although roscovitine activated p53 in cell lines with MDM2 overexpression, it was not capable of overcoming the suppressive eect of exogenous MDM2 in transient transfections. Transient transfection of BP100-luciferase with MDM2 expression plasmid into U2OS cells resulted in strong suppression of luciferase expression due to inhibition of endogenous p53 function. This phenotype could not be reversed by treatment with roscovitine (data not shown). This result suggests that because CDK inhibitors do not block p53-MDM2 binding, activation of p53 most likely requires elimination of MDM2 at the level of gene expression.
To further test the importance of MDM2 downregulation, we used an U2OS cell line that expresses tetracycline-inducible MDM2. The cells were cultured in the absence of tetracycline to induce expression of the MDM2 cDNA, followed by treatment with roscovitine. The result showed that the tetracyclineinducible MDM2 expression was relatively resistant to inhibition by roscovitine, the continued presence of high-level MDM2 blocked the induction of endogenous p53 by roscovitine (Figure 5a ). In the presence of tetracycline, the endogenous MDM2 was downregulated by roscovitine, which correlated with increase in p53 level. To con®rm this result, p53 was also transiently transfected into the p53-null mouse cell line 10(1) (p53 remains relatively stable in transiently transfected human p53-null H1299 cells). Similar to endogenous p53 in human cell lines, transiently transfected p53 was also induced by treatment with roscovitine. When the CMV-MDM2 plasmid was cotransfected with p53, the expression of exogenous CMV-driven MDM2 was not inhibited by the concentration of roscovitine used in the experiment. As expected, roscovitine did not induce accumulation of p53 in the presence of exogenous MDM2 ( Figure  5b ). These results indicate that stabilization and The tumour suppressor ARF can inhibit the ubiquitination and degradation of p53 without blocking MDM2 and p53 interaction (Sherr, 1998) . To determine whether stabilization of p53 by CDK inhibitors requires the function of ARF, a cell line derived from the ARF-null mouse was treated with roscovitine and p53 level was determined by Western blot and immuno¯uorescence staining. The results indicate that p53 level (Figure 5c ) and nuclear accumulation (data not shown) are also induced by the CDK inhibitors in the absence of ARF expression. Therefore, ARF is not essential for the induction of nuclear p53 by the CDK inhibitors.
Roscovitine does not block nuclear shuttling of p53 and MDM2
Degradation of p53 requires nuclear export of p53 and MDM2. Because the CDK phosphorylation site was located next to the major nuclear localization signal of p53, an attractive hypothesis is that inhibition of CDK may enhance the nuclear retention of p53 and reduce the rate of nuclear export. Furthermore, it has not been determined whether CDK is required for the nuclear export of MDM2. Therefore, the nuclear export of p53 and MDM2 in the presence of roscovitine was examined using a heterokaryon shuttling assay. The human choriocarcinoma JAR cells were fused with a p53/MDM2 double-null mouse cell line. JAR cells express high levels of MDM2 due to gene ampli®cation and have wild type p53, which facilitate detection of p53 and MDM2 shuttling without requiring transfection of exogenous plasmids. Double immuno¯uorescence staining of MDM2 and p53 showed that the shuttling of both p53 and MDM2 were not inhibited by roscovitine (Figure 6 ). This result rules out the possibility that roscovitine induces nuclear accumulation of p53 by blocking the nuclear export of p53 or MDM2. The result also suggests that CDC2 and CDK2 activities (which are most sensitive to roscovitine) are not required for the shuttling of p53 and MDM2.
Roscovitine induces stabilization of a p53 serine 315 mutant
Although the results described above suggest that inhibition of MDM2 expression is important for stabilization of p53, it is possible that regulation of p53 phosphorylation at serine 315 is still essential for p53 nuclear accumulation. Therefore, an Ala-315 mutant was tested for response to CDK inhibitors. The Ala-315 mutant and wild type p53 was subcloned into a tetracycline-responsive vector to prevent overexpression. When transiently transfected into 10(1) cells and induced to express the p53 proteins by removing The cdk inhibitor roscovitine activates p53 by inhibiting MDM2 expression W Lu et al tetracylcine, the Ala-315 mutant was further induced by roscovitine to a similar extent as wild type p53 (Figure 7a ). To further test the response of the exogenous p53 to roscovitine in stable expression systems, the plasmids were transfected into H1299 cells and pools of stable colonies were established in the presence of tetracycline to prevent toxicity due to p53 overexpression. The cells where then treated with roscovitine in the presence of tetracycline, which maintained a low basal expression level of p53. The result showed that even when tetracycline was present, roscovitine induced the nuclear accumulation of both wild type p53 and the Ala-315 mutant (Figure 7b) . Therefore, roscovitine induces p53 stabilization through a mechanism that is independent of the serine 315 CDK site.
Synergisitc activation of p53 by roscovitine and DNA damage
The results described above show that roscovitine stabilizes p53 through a mechanism dierent from that of many DNA damaging agents. Our previous study demonstrated that inhibition of MDM2 expression by antisense oligonucleotides can synergistically activate p53 when combined with the DNA-damaging drug camptothecin (CPT) (Chen et al., 1998) , which is a topoisomerase I inhibitor that induces DNA strand breaks. The eects of roscovitine on MDM2 led us to test whether it can also cooperate with camptothecin in p53 activation.
When MCF-7 cells stably transfected with the p53-responsive luciferase reporter were treated with dierent concentrations of roscovitine, a dose-dependent activation of p53 was reproducibly observed at concentrations below 20 mM, similar to the result in Figure 1 . CPT treatment alone induced a moderate increase of p53 activity. As expected, combination of roscovitine and CPT showed a synergistic eect in the induction of p53 transcription activity (Figure 8a ). The activity of p53 began to diminish at roscovitine concentrations over 20 mM, possibly due to the strong inhibition of general transcription by roscovitine. Furthermore, although 20 mM roscovitine alone induced p53 activation, a combination of 20 mM roscovitine and 0.5 mM CPT resulted in loss of transcription readout, possibly due to the combined toxicity by the two drugs. Removal of roscovitine led to rapid recovery of strong p53 activity after 4 h (data not shown). These results showed that when used at lower concentrations, roscovitine can cooperate with DNA damage to activate p53 without signi®cantly compromising its ability to stimulate transcription.
To determine whether roscovitine enhances the ability of camptothecin to induce cell death, MCF-7 cells were treated with the drug combinations for 3 days and cell survival were determined using an MTS assay. Treatment with 10 mM roscovitine alone only induce moderate cell death. CPT treatment alone also induced moderate levels of cell death in a dosedependent manner. However, in the presence of 10 mM roscovitine, the dose-dependent response to CPT was signi®cantly enhanced; 1 mM CPT induced 90% cell death rather than 40% when used alone (Figure 8b ). Therefore, roscovitine can sensitize cells to DNA-damaging treatment. However, although this response correlates with p53 activation, further experiments are needed to determine whether it is entirely due to activation of p53.
Discussion
The results presented in this report show that the small molecule CDK inhibitor roscovitine and olomoucin can induce stabilization and nuclear accumulation of p53, which correlates with down-regulation of MDM2 expression at the mRNA level. Because roscovitine and olomoucin induce nuclear accumulation and stabilization of p53 at concentrations that are eective for the inhibition of cyclin-dependent kinases, an attractive hypothesis is that they function by blocking the ability of CDK to phosphorylate p53. Because p53 degradation requires ecient nuclear export, phosphorylation of serine 315 near the nuclear-targeting signal may promote nuclear export and degradation of p53. However, our results show that the alanine 315 were cultured in the presence of tetracycline to suppress the transfected MDM2, or in the absence of tetracycline to induce MDM2. Cells were then treated with 20 mM roscovitine for the indicated times. p53 and MDM2 were detected by Western blot. (b) p53 expression plasmid was transiently transfected into 10(1) cells alone or in combination with a CMV-MDM2 expression plasmid. Two days after transfection, the cells were split into duplicate sets and one set was treated with roscovitine for 8 h. p53 and MDM2 were detected by Western blot. (c) The ARF-null MEF 4-9 cells were treated with roscovitine for 14 h and mouse p53 was detected by immunoprecipitation and Western blot using the Pab421 antibody
The cdk inhibitor roscovitine activates p53 by inhibiting MDM2 expression W Lu et al mutation is not sucient to stabilize p53. Furthermore, this mutant is still stabilized after roscovitine treatment, suggesting that roscovitine function by a mechanism independent of modulating serine 315 phosphorylation. Additionally, p53-MDM2 binding or p53 and MDM2 shuttling is not inhibited by the CDK inhibitors. These results suggest that the major mechanism by which CDK inhibitors induce p53 stabilization is inhibition of MDM2 expression. A recent study suggested that several drugs activate p53 function by partial inhibition of RNA polymerase II-mediated transcription . The CDK inhibitors used in our study have also been shown to have transcription-inhibitory function at concentrations that are used to inhibit CDK activity (Blaydes et al., 2000; Schang et al., 1999; Sankrithi and Eskin, 1999) . Therefore, it is possible that inhibition of MDM2 expression is part of a more general transcription inhibitory eect. This is also consistent with the observation that drug removal results in strong activation of p53 transcription. However, it is apparent that the transcription-inhibitory eect varies among dierent promoters at the concentrations of roscovitine used in our experiments. Although MDM2 expression is strongly suppressed, expression of the transfected p53-responsive reporter and endogenous p21 are induced. Therefore, MDM2 appears to be particularly sensitive to this inhibition, possibly due to its stronger dependence on a roscovitine-sensitive kinase for transcription.
Our results suggest that the p53-stimulatory eect observed for other transcription-inhibitors (such as actinomycin D, doxorubicin, H7, and a-amanitin) may also be mediated by down-regulation of MDM2 Andera and Wasylyk, 1997; Chang et al., 1999) . For example, UV irradiation which inhibits MDM2 expression as well as RNA polymerase II-mediated transcription eciently activates p53 (Wu and Levine, 1997; Ljungman et al., 1999) , resulting in the induction of p21 expression. MDM2 mRNA expression is also highly sensitive to the transcription inhibitor actinomycin D at concentrations that do not signi®cantly aect p53 and p21 transcription (Hietanen et al., 2000) . The sensitivity of MDM2 to transcription inhibition may be a physiologically important phenomenon, since UV irradiation of human skin also induces rapid increase in p53 level without increase of MDM2 (Hall et al., 1993; O'Grady et al., 1998) . It is possible that this sensitivity is part of the mechanism that makes p53 highly responsive to diverse cellular as well as extracellular stress signals that aect transcription.
Although the concentration of roscovitine we used to stabilize p53 is also sucient to inhibit CDC2 and CDK2, our results show that inhibition of CDK may not be completely responsible for down-regulation of MDM2. Transfection of more speci®c protein inhibitors of CDK individually or in combination does not activate p53, suggesting that inactivation of an unknown kinase may be responsible for down-regulation of MDM2. However, the results do not exclude There is strong biochemical evidence that serine 315 can be phosphorylated by CDK in vitro. Recently, phosphorylated serine 315 has also been found to be an in vitro substrate of the CDC14 phosphatase, which is involved in the regulation of mitosis (Li et al., 2000) . These observation again raised the possibility that serine 315 may be an important regulatory site of p53. However, previous studies failed to identify a signi®cant role for this serine residue in the biological functions of p53 and its stabilization after DNA damage. This study shows that serine 315 is also dispensible for response to CDK inhibitors. Although the results do not exclude the possibility that phosphorylation of serine 315 may regulate the nuclear import and export of p53 in certain conditions, the fact that the Ala-315 mutant is as unstable as wild type p53 suggests that constitutive phosphorylation of serine 315 is not essential for p53 nuclear export and degradation.
DNA damage by chemotherapy drugs and ionizing irradiation activate p53 mainly through inducing phosphorylation of p53, which leads to inhibition of MDM2 binding and functional activation of latent p53. However, activation of p53 also results in the induction of MDM2 expression, which may limit the degree of p53 activation to some extent. Therefore, other methods that can block MDM2 expression should be able to cooperate with DNA damage to activate p53. This concept was supported by experiments using antisense oligonucleotides to inhibit MDM2 expression (Chen et al., 1998) . A synergistic eect is expected if two agents target the same pathway through dierent, but complementary mechanisms. The direct eect of roscovitine on MDM2 expression suggests that it should be able to cooperate with DNAdamaging agents that do not work by down-regulation of MDM2. Our result shows that this synergistic eect can indeed be obtained using lower concentrations of roscovitine. The activation of p53 correlates with increased sensitivity to camptothecin-induced cell death. Therefore, in addition to its inhibitory eect on the cell cycle, roscovitine may be useful as a sensitizing agent for DNA-damaging chemotherapy drugs in the activation of p53.
Our results are consistent with previous experiments in showing that inhibition of MDM2 expression is an ecient method to induce p53 stabilization . The eects of the small molecule CDK inhibitors suggest the existence of a kinase that can be targeted to achieve pharmacological inhibition of MDM2. It remains to be determined whether the same kinase target is involved in the down-regulation of MDM2 expression and general transcription inhibition by the CDK inhibitors. If MDM2 expression is speci®cally regulated by a unique kinase, it may be possible to achieve more speci®c inhibition of MDM2 by identifying the kinase and developing speci®c inhibitors. Even in the absence of such a speci®c target, the sensitivity of MDM2 expression to low concentrations of transcription inhibitors may still be a useful feature to consider when designing drug combinations. Roscovitine and olomoucin have shown potent anti-tumor activities in cell culture and in animal models and are promising compounds for cancer treatment (Hajduch et al., 1999) . When this manuscript was being prepared, a study by Blaydes et al. (2000) also demonstrated a cooperative eect of roscovitine with X-ray in synergistic activation of p53. Our results suggest a mechanism and the rationale for of such combination treatments.
Materials and methods
Cell lines and reagents
H1299 (lung carcinomas, p53-null), HCT116 (colon carcinoma, wt p53), U2OS (osteosarcoma, wt p53), MCF-7 (breast carcinoma, wt p53), and 10(1) (p53-null MEF) were provided by Dr Arnold J Levine. SK-N-SH (neuroblastoma, wt p53), WI38 (lung ®broblast, wt p53), SJSA (osteosarcoma, wt p53, MDM2 ampli®cation), and JAR (choriocarcinoma, wt p53, MDM2 ampli®cation) were obtained from the ATCC. MCF7-BP100-luc cells were generated in a previous study . MDM2/p53 double-null MEF 174.1 was kindly provided by Guillermina Lozano (McMasters et al., 1996) . A clonal subline 174.1.1 used for cell fusion was generated by single-cell clonging of 174.1. The ARF-null 4-9 MEF cell line was kindly provided by Charles Sherr. All cells were grown in DMEM with 10% fetal bovine serum (FBS). Roscovitine and olomoucin (Sigma) were used at 5 ± 30 and 100 mM respectively. Ala-315 mutant of p53 was generated using the QuickChange mutagenesis kit (Stratagene). Wild type p53, mutant p53, and human MDM2 cDNA were cloned into the tetracycline-repressible pUHG10.3 vector. Stable cell lines were established by cotransfection of pUHG10.3-p53 or pUHG10.3-MDM2 plasmids with the pUHD15.1 activator plasmid (Gossen and Bujard, 1992) .
Western blot
Cells were lysed in RIPA buer (1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mM Tris pH 7.4, 150 mM NaCl, and 1 mM PMSF), centrifuged for 5 min at 10 000 g, and the insoluble debris were discarded. Cell lysate (20 ± 200 mg protein) was fractionated by SDS ± PAGE and transferred to Immobilon P ®lters (Millipore). The ®lter was blocked for 1 h with phosphate-buered saline (PBS) containing 5% non-fat dry milk, 0.1% Tween-20 and then incubated for 1 h with anti-MDM2 monoclonal antibody 3G9 (Chen et al., 1993) or anti-p53 monoclonal antibody DO-1 in PBS containing 5% non-fat dry milk. Bound primary antibody was detected by incubating for 1 h with HRP-goat-anti-mouse IgG. The ®lter was developed using the ECL-plus reagent (Amersham). To detect polyubiquitinated p53, SJSA cells were lysed in ice-cold hypotonic buer (20 mM Tris pH 7.4, 5 mM MgC1 2 , 8 mM KCl, 1 mM DTT) using a Dounce homogenizer. The lysate was centrifuged for 5 min at 10 000 g at 48C and the supernatant was used for Western blot.
Northern blot
Total cellular RNA was isolated using the RNeasy Kit (Qiagen). Twenty micrograms of total RNA were fractionated on a formaldehyde denaturing gel and transferred onto a Biotrans membrane (ICN). The ®lter was hybridized with a random-primed probe synthesized using a 1350 bp MDM2 cDNA fragment (from the translation start codon to the NcoI site at codon 450). Hybridization was carried out in a buer containing 1% SDS, 1 M NaCl, and 10% dextransulfate for 18 h at 658C. The ®lter was washed with 26SSC buer (0.3 M NaCl, 0.03 M Na-Citrate) and exposed. For detection of GAPDH mRNA (glyceraldehyde-phosphate dehydrogenase), the ®lter was stripped and rehybridized with a full-length 1.2 kb human GAPDH cDNA probe. Actinomycin D was used at 16 mM to inhibit transcription.
Determination of p53 halflife
SJSA cells were treated with 30 mM rosovitine for 20 h. The cells were incubated with DMEM (without methionine) with 2% dialyzed FBS, 50 mCi/ml 35S-EXPRESS (NEN) for 1 h and then refed with regular medium. Roscovitine was also added to 30 mM during the labeling and chase. Sample plates were collected at indicated time points and lysed with lysis buer (50 mM Tris, pH 8.0, 5 mM EDTA, 150 mM NaCl, 0.5% NP40, and 1 mM PMSF). Cell lysate with identical levels of radioactivity (*2610 7 c.p.m.) were immunoprecipitated with Pab1801, washed with 50% SNNTE buer (25 mM Tris, pH 7.4, 2.5 mM EDTA, 2.5% sucrose, 1% NP-40, and 250 mM NaCl), and fractionated by SDS ± PAGE. p53 was detected by autoradiography.
Immunofluorescence staining
Cells cultured on chamber slides were ®xed with acetonemethanol (1 : 1) for 3 min at room temperature, blocked with PBS+10% normal goat serum (NGS) for 20 min, and incubated with anti-p53 Pab1801 hybridoma supernatant (1 : 10 dilution) or anti-MDM2 2A9 hybridoma supernatant (1/100 dilution) in PBS+10% NGS for 2 h. The slides were washed with PBS+0.1% Triton X-100, incubated with FITC-goat-anti-mouse IgG in PBS+10% for 1 h, washed with PBS+0.1% Triton X-100 and mounted.
Heterokaryon assay
Human cells (JAR) were mixed with p53/MDM2 double-null mouse cells (174.1.1), co-cultured for 20 h on chamber slides and pre-treated with 30 mM roscovitine for 4 h and 100 mM cyclohexamide for 30 min. The cells were then treated with PBS+50% PEG (Sigma, molecular weight 3350) for 2 min, washed with medium, and incubated for 1 h in the presence of cyclohexamide and roscovitine. The cells were ®xed and stained for MDM2 using 2A9 and rhodamine-goat-antimouse IgG as described above, and then stained for p53 using FITC-conjugated DO-1 antibody. Before mounting, the slides were incubated with PBS+1 ng/ml DAPI to stain DNA.
